Mass rollout of weight loss jabs begins on NHS
Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years.
The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested.
From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems.
Patients previously needed to access the drugs through a special weight loss service.
But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout.
And pharmacy experts also said there could be pressure on supplies of the drug.
In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea.
Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription.
Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today.
'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people.
'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions.
'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.'
Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments.
'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow.
GLP-1s like #Ozempic, #Saxenda, #Wegovy, or #Mounjaro are not an easy #weightloss hack.
Find out more about:🔵what they are ❓🔵how they're used 💊🔵who they help 💪
🔗Learn more: https://t.co/GY4a7VRAgF pic.twitter.com/Agiav8ryfU
— EU Medicines Agency (@EMA_News) January 4, 2025
She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely.
'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss.
'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.'
Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'.
She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.'
Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately.
'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly.
'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy.
'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice.
'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it.
'The biggest concern we have is that prescribing these medications alone misses the point.
'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up.
'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.'
Around 29% of the adult population in the UK is obese.
Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity.
'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay.
'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
The Rare Statement Ozzy Osbourne Once Made About Living With Parkinson's Disease
Ozzy Osbourne has died at 76. He discussed his Parkinson's Disease diagnosis in recent years. The star spoke about the physical symptoms, like walking issues, and mental symptoms, like depression. Ozzy Osbourne has passed away at 76, weeks after performing a final show. The musician faced a number of health challenges over the years, from contracting COVID-19 to a neck operation to dealing with symptoms related to his battle with Parkinson's disease. Though the 'Patient Number 9' singer wasn't always open about his health. Over the last few years, the star revealed the physical and mental challenges that accompanied his Parkinson's. The rocker first revealed his diagnosis in 2020, which he said was 'terribly challenging' in an interview with Good Morning America, while his wife, Sharon, explained: 'There's so many different types of Parkinson' it does affect certain nerves in your body. And it's—it's like you have a good day, and then a really bad day.' According to the Parkinson's Foundation, Parkinson's disease is a progressive neurodegenerative disorder that affects dopamine-producing neurons in the brain, resulting in both motor and non-motor symptoms including tremors, limb rigidity, cognitive impairment, depression, and balance issues. Depression is another Parkinson's-related symptom that Ozzy dealt with. He explained that he 'reached a plateau,' where 'nothing really felt great,' which prompted him to begin taking antidepressants. 'You learn to live in the moment,' Ozzy continued. 'You don't know when you're gonna wake up and you ain't gonna be able to get out of bed. But you just don't think about it.' After Osbourne's 'very major [neck] operation,' which his wife, Sharon Osbourne previously said 'would determine the rest of his life,' the Black Sabbath rocker faced some complications. He reported that he experienced nerve pain, per an interview with The Guardian. 'It got so was f*cking agony,' he explained. The side effects from the surgery only added to the difficulties Ozzy already faced with Parkinson's. Some of his symptoms included motor issues, like walking. 'You think you're lifting your feet, but your foot doesn't move,' he explained in the same interview. 'I feel like I'm walking around in lead boots.' An official cause of death has yet to be reported. Our thoughts are with the Osbourne family at this time. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
2 hours ago
- Yahoo
'Selfless' mum wants to live life to fullest after devastating diagnosis
A 'KIND hearted' and 'selfless' mum of a two-year-old is fundraising for essential costs to prolong her life after she was given a devastating cancer diagnosis. Zoë Handscomb-Edwards, 44, was diagnosed with an aggressive cancer in March 2023, when she was 16 weeks pregnant with her first child, Penelope. The news came after she attended the doctors with what she thought was a pulled muscle in her leg. This was later diagnosed as an extremely rare PEComa. To donate to the GoFundMe, click here. The diagnosis followed an ultrasound and MRI, but she could not undergo any further scans due to her pregnancy. Zoë, who works for the RNLI and lives in Bournemouth, said: 'Hearing somebody say those words, it was like my world just dropped away. READ MORE: "That's what I say was the worst day of my life - when we just left the hospital and they had no information for us. All I knew was that I was going to be referred to the sarcoma clinic. "From then on, it was incredible. Every single bit of NHS support that I've had from that point has been absolutely first class". Zoë and Rob's daughter, Penelope, has now turned two years old (Image: Zoë Handscomb-Edwards) Shortly after giving birth to her daughter in July 2023, Zoë underwent a PET scan where she was told she had six months to two years to live due to the cancer spreading to her lungs, hip, neck and lower back. Despite the odds and a stage four diagnosis, two years later, Zoë is living her life to the fullest with an admirably positive attitude, supported by family and friends and in particular, her husband, Rob. Zoë said: 'I don't know how much time I've got. Everything could change in 10 days or I could have 10 years - they don't know. "I just put one foot in front of the other and I've got this amazing support around me. "This whole thing has made me realise how resilient I am and how people can be." She has also stepped out of her comfort zone by sharing her story publicly on her Instagram page, hoping to support others in similar positions. She particularly wants to help those with the same, ultra-rare diagnosis and raise awareness of the help available to those living with cancer. Zoë said: 'Macmillan has been amazing and - there's so much support out there and there's so many incredible people, and I think when you first get diagnosed, it's so overwhelming and you don't get told all these things. Zoë continues to be positive (Image: Zoë Handscomb-Edwards) "You have so many questions about what this means and who am I going to be, what does my life look like and how long is my life going to be? You need support from people who can help you navigate that." Rob has now set up a GoFundMe page on behalf of Zoë, to raise essential funds for drugs, therapies and treatment to ensure she does not go without the expensive care needed over the upcoming months and years. In particular, Zoë wishes to raise money to help her create memories with her family, making the most of every moment. Rob said: 'Zoë is so much more than her diagnosis. She is the most loving, kind-hearted, and selfless person I know. Even before her diagnosis, Zoë was always the first to offer help to anyone in need. 'Whether it was supporting friends through tough times, volunteering in the community or simply offering a listening ear, Zoë's generosity and compassion have touched so many lives. "Now, it's our turn to rally around her.'
Yahoo
4 hours ago
- Yahoo
NHS on the hunt for ‘precision-matched' blood donors
The NHS is searching for blood donors with rare blood types so it can ensure patients in need can receive 'precision-matched' blood. Scientists have tested tens of thousands of blood donors to see if they have rare blood types in a UK-first. The blood from donors with rare blood types will be collected and frozen so it can be used to help other people with the same type of blood. It will also be available should the donor be in a situation where they themselves need a blood transfusion. The new drive to find precision-matched blood donors comes to help people who are at risk of blood transfusion side effects. NHS Blood and Transplant (NHSBT) said that blood matching is 'vital' due to the complexity of blood groups – there are 362 known blood types. So far its scientists have DNA-tested the blood types of 77,000 donors as part of a research project. This is the first time that blood types have been DNA tested in the UK at-scale, NHSBT said. Dozens of rare blood donors have been identified during the process and it is hoped the number will rise to hundreds. This means that blood from these donors can be used as 'personalised, precision-matched transfusion' for those in need. This can help avoid severe transfusion reactions – where the body sees the transfused blood as 'foreign' and rejects it. People who are particularly at risk of these reactions are those who regularly receive blood donations including those with sickle cell disorder and thalassaemia. Experts hailed the project as the 'first major step' towards rolling out precision-matched blood more widely. Dr Gail Miflin, chief medical officer at NHSBT, said: 'Taking these 77,000 donors and testing their blood to such a precise level has been an incredible undertaking and will work to significantly change the way we issue blood – especially to those patients at higher risk of transfusion related reactions. 'We will be able to match to an increasing number of blood groups, ensuring that patients have blood that is most similar to their own and reducing the risk of any reactions. It is an example of just how we are driving innovation which can radically improve patient outcomes.' NHSBT's genomics programme director, Kate Downes, added: 'This inventory of blood will enhance our capacity to find units with rare blood groups for difficult to match patients as well as provide better matched units for patients who have an increased risk of transfusion reactions, aiding us in our mission to save and improve even more lives. 'This genotyping is a first major step towards rolling out precision matched blood more widely, which would be a landmark change in how blood is matched.'
